Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Larimar Therapeutics (LRMR) Accounts Payables (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Accounts Payables for 7 consecutive years, with $3.3 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Accounts Payables rose 26.34% year-over-year to $3.3 million, compared with a TTM value of $3.3 million through Sep 2019, up 26.34%, and an annual FY2018 reading of $3.6 million, up 18.87% over the prior year.
  • Accounts Payables was $3.3 million for Q3 2019 at Larimar Therapeutics, up from $2.1 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $7.5 million in Q4 2015 and bottomed at $1.9 million in Q1 2017.
  • Average Accounts Payables over 5 years is $3.4 million, with a median of $3.2 million recorded in 2019.
  • The sharpest move saw Accounts Payables surged 294.58% in 2015, then plummeted 65.68% in 2016.
  • Year by year, Accounts Payables stood at $7.5 million in 2015, then tumbled by 65.68% to $2.6 million in 2016, then increased by 17.42% to $3.0 million in 2017, then grew by 18.87% to $3.6 million in 2018, then fell by 7.55% to $3.3 million in 2019.
  • Business Quant data shows Accounts Payables for LRMR at $3.3 million in Q3 2019, $2.1 million in Q2 2019, and $3.2 million in Q1 2019.